Purβ Inhibitors
Chemical inhibitors of Purβ can interfere with its activity through multiple cellular signaling pathways by targeting key regulatory kinases and enzymes that are essential for the functional modulation of Purβ's interaction partners. Bisindolylmaleimide I, for instance, is a specific protein kinase C (PKC) inhibitor, which can inhibit the phosphorylation of PKC substrates. Since Purβ interacts with PKC substrates, the inhibition of PKC could lead to reduced activity of these substrates, which in turn may result in decreased Purβ activity due to its reliance on phosphorylated interaction partners for functionality. Similarly, Staurosporine, a broad-spectrum protein kinase inhibitor, can inhibit various kinases that may phosphorylate proteins that interact with Purβ, hence indirectly inhibiting Purβ activity. The PI3K inhibitors LY294002 and Wortmannin can interrupt the PI3K signaling pathway, which is integral to many cellular processes including those that may involve Purβ's functional partners, leading to a downstream inhibition of Purβ activity.
Further, PD98059 and U0126, as inhibitors of the mitogen-activated protein kinase kinase (MEK), disrupt the MAPK/ERK pathway, which is known to regulate transcription factor activity that can be linked to Purβ function. By inhibiting MEK, these compounds indirectly prevent the activation of transcription factors and other molecules that are crucial for Purβ's activity. In a similar vein, SB203580 and SP600125, which inhibit p38 MAPK and c-Jun N-terminal kinase (JNK) respectively, can affect the signaling pathways that involve transcription factors interacting with Purβ. This disruption can result in the functional inhibition of Purβ. Additionally, H-89 targets protein kinase A (PKA), and by inhibiting PKA-mediated phosphorylation processes, it can lead to an indirect inhibition of Purβ. The selective PKC inhibitor GF109203X also operates on the same principle, impeding the phosphorylation of Purβ interaction partners. Lastly, the tyrosine kinase inhibitors Lapatinib and Sorafenib are capable of disrupting signaling pathways via EGFR, HER2/neu, VEGFR, and PDGFR receptors, which can be essential for the activity of molecules that interact with Purβ, thereby inhibiting Purβ activity through these pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). Purβ is known to interact with PKC substrates, and inhibition of PKC by Bisindolylmaleimide I would inhibit the phosphorylation of these substrates, potentially leading to reduced Purβ activity as phosphorylation is critical for the function of many interaction partners of Purβ. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of a wide range of protein kinases. Purβ's activity is modulated by phosphorylation, which is a process often mediated by protein kinases. Staurosporine's broad kinase inhibition properties can inhibit the kinases that phosphorylate Purβ's interaction partners, thereby inhibiting Purβ's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). Since PI3K signaling is crucial for many cellular functions including transcription factor activity, LY294002 can inhibit the pathways that are essential for Purβ's functional partners, potentially leading to an inhibition of Purβ activity. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89 is a protein kinase A (PKA) inhibitor. Purβ is known to interact with PKA substrates, and inhibition of PKA by H-89 would inhibit the phosphorylation of these substrates, potentially leading to reduced Purβ activity as phosphorylation is critical for the function of many interaction partners of Purβ. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K. By inhibiting PI3K, wortmannin can affect downstream signaling pathways that are crucial for the activation of transcription factors and other molecules that could interact with Purβ, thus inhibiting Purβ's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. The MAPK/ERK pathway can regulate transcription factor activity, and by inhibiting MEK, PD98059 could inhibit the activity of transcription factors or other molecules interacting with Purβ, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a kinase involved in stress and inflammatory responses. By inhibiting p38 MAPK, SB203580 can disrupt signaling pathways involving transcription factors and other molecules that interact with Purβ, resulting in the inhibition of Purβ activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the stress-activated protein kinase pathway. Inhibition of JNK by SP600125 can lead to alterations in transcription factor activity, which in turn can inhibit Purβ's activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. By inhibiting MEK1/2, U0126 can impair the function of transcription factors or other molecules that interact with Purβ, leading to its functional inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets the EGFR and HER2/neu receptors. By inhibiting these receptors, Lapatinib can disrupt downstream signaling pathways that involve transcription factors or other molecules that interact with Purβ, leading to its functional inhibition. | ||||||